DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
DarioHealth Corp. (Nasdaq: DRIO) has appointed Eitan Shay as Chief Product Officer and Arnaud Robert as Strategic Advisor to the CEO. These strategic appointments aim to enhance Dario's digital therapeutics platform amidst increasing market demand. Eitan Shay brings extensive experience from Livongo, Teladoc Health, and Meta Platforms. On April 3, 2023, Shay was granted stock options to purchase 100,000 shares at $3.93, alongside performance-based options for an additional 80,000 shares. Dario's innovative solutions empower individuals to manage chronic conditions more effectively, reinforcing the company's commitment to continuous improvement in healthcare delivery.
DarioHealth Corp. (Nasdaq: DRIO) has announced a significant contract with a leading nationwide Pharmacy Benefits Manager (PBM) to provide its digital therapeutics, including a diabetes solution, starting in Q2 2023. This contract marks the first outcome of Dario's strategic partnership with Sanofi and is expected to replace the PBM's existing diabetes solution. The initiative aims to enhance Dario's portfolio in the employer and payer markets, generating revenue growth through 2023. The partnership is a vital step in Dario's strategy to expand its digital health solutions, demonstrating the value of collaborations in the rapidly growing digital therapeutics sector.
DarioHealth Corp. (Nasdaq: DRIO) has entered into a strategic partnership with Amwell (NYSE: AMWL), integrating Dario's cardiometabolic solutions into Amwell's digital care delivery platform, which covers over 90 million lives. This collaboration aims to enhance the care experience for individuals with conditions such as diabetes and hypertension by providing access to Dario's personalized digital health solutions. The Dario cardiometabolic suite will be available to Amwell customers in the second half of 2023, promoting a seamless member journey and supporting better health management.